Clinical Trial Update: Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bezafibrate’s effect on muscle metabolism in patients with fatty acid oxidation defects; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carnitine Palmitoyltransferase Ii Deficiency
• Very Long-chain Acyl-coa Dehydrogenase Deficiency

Drugs mentioned

• Bezafibrate (bezafibrate)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Carnitine Palmitoyltransferase II Deficiency, Very Long Chain Acyl Coa Dehydrogenase Deficiency | Phase 2 | Status: COMPLETED